This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation.

This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation. And, this trial is approved by medical ethics committee of hebei yanda hospital. Also, the trial has got a registry code "ChiCTR-OOC-15005759" in China clinical trial registry. Researchers will conduct thsi trial from 2015/02 to 2017/12, and 100 recurrent high-grade glioma with IDH1/2 mutation patients will be recruited. Patients who are recruited will get PCV chemotherapy in ether Hebei Yanda Hospital or Beijing Tiantan hospital, and get follow-ups from clinicians.

Inclusion Criteria:

• A diagnosis of high-grade glioma was established by pathological method,and the recurrency of the disease is ongoing.
• The report of the pathological diagnosis contained the status of IDH gene, and showed that IDH1/2 mutation existed.
• The age of the patient is between 18 years old and 70 years old.
• The condition of the patient permits the procedure of chemotherapy using PCV schema.
• The patient is informed consent, and willing to join in this research.

Exclusion Criteria:

• The diagnosis is not recurrent high-grade glioma.
• The diagnosis of high-grade glioma was not established by pathological method.
• No molecular neuropathological report is available, or the report showed that IDH1/2 mutation did not exist.
• The age of the patient does not meet the requirement of this research.
• The condition of the patient does not permit the procedure of chemotherapy using PCV schema.
• There are other conditions that the clinicians believe that the PCV chemotherapy is not appropriate for the patient.
• The patient is not willing to join in this research.